1. Wolff D, Nee S, Hickey NS, Marschollek M. Risk factors for COVID-19 severity and fatality: a structured literature review. Infection. 2020;49(1):15–28. https://doi.org/10.1007/s15010-020-01509-1
2. Pavey H, Kulkarni S, Wood A, Ben-Shlomo Y, Sever P, McEniery C, et al. Primary hypertension, anti-hypertensive medications and the risk of severe COVID-19 in UK Biobank. PLoS One. 2022;17(11):e0276781. https://doi.org/10.1371/journal.pone.0276781
3. Farshbafnadi M, Zonouzi SK, Sabahi M, Dolatshahi M, Aarabi MH. Aging & COVID-19 susceptibility, disease severity, and clinical outcomes: The role of entangled risk factors. Exp Gerontol. 2021;(154):111507. https://doi.org/10.1016/j.exger.2021.111507
4. Bellocchi C, Carandina A, Montinaro B, Targetti E, Furlan L, Rodrigues GD, et al. The interplay between autonomic nervous system and inflammation across systemic autoimmune diseases. Int J Mol Sci. 2022;23(5):2449. https://doi.org/10.3390/ijms23052449
5. Petterson JL, McPhee BN, Wu Y, O'Brien MW. Does COVID-19 influence the sympathetic regulation of blood pressure? J Physiol. 2021;599(22):4951–4953. https://doi.org/10.1113/JP282362
6. Kolpakov VV, Ananyev VN, Fateeva NM, Zhidkikh AS. Ad reno- and cholinoreactivity of the vascular system under the influence of low temperature. Int J Circumpolar Health. 2001;60(4):506 511. https://doi.org/10.1080/25761900.2022.12220625
7. Jong-Ho N, Jong IP, Byung-Jun K, Hun-Tae K, Jung Hee L, Chan-Hee L, et al. Clinical impact of blood pressure variability in patients with COVID-19 and hypertension. Blood Pres sure Monitoring. 2021;26(5):348–356. https://doi.org/10.1097/MBP.0000000000000544
8. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28:1–39. e14. https://doi.org/10.1016/j.echo.2014.10.003
9. Шуркевич Н. П., Ветошкин А. С., Карева М. А. Артериальная гипертензия и СOVID-19 в условиях десинхронизирующих факторов арктической вахты. Российский кардиологический журнал. 2025;30(3):5914. https://doi.org/10.15829/1560 4071-2025-5914
10. Шуркевич Н. П., Ветошкин А. С., Карева М. А. Модуля ции циркадного ритма артериального давления в формуле модели риска COVID-19 у лиц с артериальной гипертензией в условиях вахты в Арктике. Артериальная гипертензия. 2024;30(5):487 496. https://doi.org/10.18705/1607-419X-2024-2441
11. Временные методические рекомендации «Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Версия 14» (утв. Министерством здравоохранения РФ 27 декабря 2021 г
12. Petrakis D, Margină D, Tsarouhas K, Tekos F, Stan M, Ni kitovic D, et al. Obesity — a risk factor for increased COVID-19 prevalence, severity and lethality (Review). Mol Med Rep. 2020;22(1):9–19. https://doi.org/10.3892/mmr.2020.11127
13. Porzionato A, Emmi A, Barbon S, Boscolo-Berto R, Stecco C, Stocco E, et al. Sympathetic activation: a potential link between comorbidities and COVID-19. FEBS J. 2020;287(17):3681 3688. https://doi.org/10.1111/febs.15481
14. Pongratz G, Straub RH. Chronic effects of the sympathetic nervous system in inflammatory models. Neuroimmunomodulation. 2023;30(1):113–134. https://doi.org/10.1159/000530969
15. Abe C, Katayama C, Bazek M, Nakamura Y, Ohbayashi K, Horii K, et al. Repeated activation of C1 neurons in medulla oblongata decreases anti-inflammatory effect via the hypofunction of the adrenal gland adrenergic response. Brain Behav Immun. 2023;111:138–150. https://doi.org/10.1016/j.bbi.2023.04.003
16. Nagai M, Fujiwara T, Kario K. Day-to-day blood pressure variability and severity of COVID-19: is sympathetic overdrive a potential link? J Clin Hypertens (Greenwich). 2021;23(9):1681 1683. https://doi.org/10.1111/jch.14337
17. Zhang Y, Agnoletti D, Blacher J, Safar ME. Blood pressure variability in relation to autonomic nervous system dysregulation: the X-CELLENT study. Hypertens Res. 2012;35(4):399–403. https://doi.org/10.1038/hr.2011.203
18. Гапон Л. И., Шуркевич Н. П., Ветошкин А. С., Губин Д. Г. Ритмы артериального давления и частота сердечных сокращений у лиц с артериальной гипертонией в условиях Крайнего Севера. Клиническая медицина. 2006;84 (2):39–44.
19. Jagannatha GNP, Yasmin AAADA, Pradnyana IWAS, Kamardi S, Pradnyaandara IGBMA, Pangkahila EE, et al. Therapeutic target and clinical impact of day-to-day blood pressure variability in hypertensive patients with COVID-19. Hypertens Res. 2023;(46):165–174. https://doi.org/10.1038/s41440-022-01077-x
20. Januszewicz A, Wojciechowska W, Prejbisz A, Dobrowol ski P, Rajzer M, Kreutz R. Impact of the COVID-19 pandemic on blood pressure control and cardiovascular risk profile in patients with hypertension. Pol Arch Intern Med. 2021;131(10):16129. https://doi.org/10.20452/pamw.16129
21. Nam JH, Park JI, Kim BJ, Kim HT, Lee JH, Lee Ch, et al. Clinical impact of blood pressure variability in patients with COVID-19 and hypertension. Blood Press Monit. 2021;26(5):348 356. https://doi.org/10.1097/MBP.0000000000000544
22. He C, Liu C, Yang J, Tan H, Ding X, Gao X, et al. Prognostic significance of day-by-day in-hospital blood pressure variability in COVID-19 patients with hypertension. J Clin Hypertens (Green wich). 2022;24(3):224–233. https://doi.org/10.1111/jch.14437
23. Li FK, An DW, Guo QH, Zhang YQ, Qian JY, Hu WG, et al. Day-by-day blood pressure variability in hospitalized patients with COVID-19. J Clin Hypertens (Greenwich). 2021;23(9):1675–1680. https://doi.org/10.1111/jch.14338
24. Fedorowski A, Fanciulli A, Raj SR, Sheldon R. Cardiovascular autonomic dysfunction in post-COVID-19 syndrome: a major health-care burden. Nat Rev Cardiol. 2024;21(6):379–395. https://doi.org/10.1038/s41569-023-00962-3
25. Инюткина А. А., Никулина В. П., Годков М. А. Особенности иммунного ответа при COVID-19. Журнал им. Н. В. Склифосовского «Неотложная медицинская помощь». 2023;12(1):122 129. https://doi.org/10.23934/2223-9022-2023-12-1-122-129
26. Codo AC, Davanzo GG, Monteiro LB, de Souza GF, Muraro SP, Virgilioda-Silva JV, et al. Elevated glucose levels favor SARS-CoV-2 infection and monocyte response through a HIF-1α/glycolysis-dependent axis. Cell Metab. 2020;32(3):437–446.e5. https://doi.org/10.1016/j.cmet.2020.07.007